Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Early dupilumab treatment may protect against asthma in young children with eosinophilic esophagitis (EoE). A retrospective study found that kids receiving dupilumab had significantly fewer new asthma diagnoses compared to those on oral budesonide. Researchers believe dupilumab's ability to target the underlying type 2 inflammatory pathway — rather than just local inflammation — may be the key driver.
Young children with eosinophilic esophagitis (EoE) treated with dupilumab were significantly less likely to develop asthma than those treated with oral budesonide, according to a retrospective cohort study presented at the ACAAI Annual Scientific Meeting. Researchers analyzed data from the TriNetX Research Network (2016–2026), focusing on children aged 6 and under — a group particularly prone to overlapping allergic conditions driven by type 2 inflammation.
The theory behind the findings: dupilumab blocks the shared inflammatory pathway underlying multiple allergic diseases, potentially offering broader protection, while budesonide acts more locally. Notably, not only did fewer dupilumab-treated kids develop asthma — they also had fewer total asthma-related medical visits over time.
By the Numbers:
Why it matters: These findings suggest that early dupilumab treatment in young children with EoE may do double duty — managing the esophageal condition while also reducing asthma risk. Prospective longitudinal studies are still needed to confirm the effect, but the data offer a compelling case for a more holistic approach to treating pediatric allergic disease.
